Authors: PLAIZIER MABD VANLINGEN A VANDIEREN EB TEULE GJJ

Citation: Mabd. Plaizier et al., THEORETICAL-MODEL TO QUANTIFY DOSE HETEROGENEITY AND PREDICT MYELOTOXICITY FOR BONE METASTASES TREATMENT, The Journal of nuclear medicine, 39(5), 1998, pp. 325-325

Authors: DEBREE R ROOS JC PLAIZIER MABD QUAK JJ VANKAMP GJ DENHOLLANDER W SNOW GB VANDONGEN GAMS

Citation: R. Debree et al., SELECTION OF MONOCLONAL-ANTIBODY E48 IGG OR U36 IGG FOR ADJUVANT RADIOIMMUNOTHERAPY IN HEAD AND NECK-CANCER PATIENTS, British Journal of Cancer, 75(7), 1997, pp. 1049-1060

Authors: VANDERMEER NJM OOMEN MWN NOORDEGRAAF AV PIJPERS RJ PLAIZIER MABD DEVRIES PMJM

Citation: Njm. Vandermeer et al., DOES IMPEDANCE CARDIOGRAPHY RELIABLY ESTIMATE LEFT-VENTRICULAR EJECTION FRACTION, Journal of clinical monitoring, 12(1), 1996, pp. 5-9

Authors: VANDIEREN EB PLAIZIER MABD VANLINGEN A ROOS JC BARENDSEN GW TEULE GJJ

Citation: Eb. Vandieren et al., ABSORBED DOSE DISTRIBUTION OF THE AUGER EMITTERS GA-67 AND I-125 AND THE BETA-EMITTERS CU-67, Y-90, I-131, AND RE-186 AS A FUNCTION OF TUMOR SIZE, UPTAKE, AND INTRACELLULAR-DISTRIBUTION, International journal of radiation oncology, biology, physics, 36(1), 1996, pp. 197-204

Authors: JONKHOFF AR PLAIZIER MABD OSSENKOPPELE GJ TEULE GJJ HUIJGENS PC

Citation: Ar. Jonkhoff et al., HIGH-DOSE GA-67 THERAPY IN PATIENTS WITH RELAPSED ACUTE-LEUKEMIA - A FEASIBILITY STUDY, British Journal of Cancer, 72(6), 1995, pp. 1541-1546

Authors: PLAIZIER MABD ROOS JC TEULE GJJ VANDIEREN EB DENHOLLANDER W HAISMA HJ DEJAGER RL VANLINGEN A

Citation: Mabd. Plaizier et al., COMPARISON OF NONINVASIVE APPROACHES TO RED MARROW DOSIMETRY FOR RADIOLABELED MONOCLONAL-ANTIBODIES, European journal of nuclear medicine, 21(3), 1994, pp. 216-222